August 5, 2022
Life Sciences
  • Amgen Inc. secured a deal to buy ChemoCentryx Inc. for $3.7 billion, giving the biotech company access to the potential blockbuster drug Tavneos. The drug is used to treat patients with a rare type of blood vessel inflammation that generated $5.4 million in sales in the first full quarter after its regulatory approval. Amgen reported second-quarter revenue of $6.59 billion, a 1 percent jump from the year-ago period fueled by a 13 percent rise in sales of its osteoporosis drug Prolia. (Article here)